8-K: Onconetix Amends Forbearance Agreement with Veru, Increases Payment Percentage

Onconetix, Inc. has amended its forbearance agreement with Veru Inc., delaying a payment and increasing the percentage of future transaction proceeds owed to Veru.

Summary

• Onconetix, Inc. has modified its agreement with Veru Inc. regarding outstanding payments related to a previous asset purchase.
• The amendment waives the due date for October 2024 cash receipt payments until Onconetix receives at least $97,000 from its equity line of credit.
• In exchange for the waiver, Onconetix will increase its payments to Veru from 20% to 25% of net proceeds from future financing and strategic transactions through June 30, 2025.
• The original asset purchase agreement involved a total consideration of $20 million, with various payment terms and amendments over time.
• The initial payment was $6 million, followed by a $4 million note, and two $5 million notes due at later dates.
• Previous amendments included the satisfaction of the $4 million note with a $1 million payment and the issuance of preferred stock, and extensions to the due dates of the $5 million notes.

Sentiment

Score: 3

Explanation: The document indicates financial strain and increased obligations, suggesting a negative outlook for the company.

Positives

• Onconetix has secured a waiver for the immediate payment of cash receipts due to insufficient cash reserves.
• The company has gained additional time to secure financing to meet its obligations to Veru.

Negatives

• Onconetix is facing cash flow issues, as evidenced by the need for a payment waiver.
• The company has increased its payment obligations to Veru from 20% to 25% of future transaction proceeds, which could impact future profitability.
• The company is reliant on securing at least $97,000 from its equity line of credit to trigger the delayed payment.

Risks

• Onconetix's ability to secure the necessary financing to meet its obligations to Veru remains a risk.
• The increased payment percentage to Veru could reduce the company's financial flexibility.
• The company's reliance on its equity line of credit for immediate cash needs indicates potential financial instability.

Future Outlook

Onconetix will need to secure at least $97,000 from its equity line of credit to trigger the delayed payment to Veru and will pay 25% of net proceeds from future financing and strategic transactions to Veru through June 30, 2025.

Management Comments

• Karina M. Fedasz, Interim Chief Financial Officer, signed the report on behalf of Onconetix, Inc.

Industry Context

This announcement reflects the challenges faced by smaller biotech companies in managing their financial obligations and securing funding, which is a common theme in the industry.

Comparison to Industry Standards

• Many small biotech companies rely on debt financing and strategic partnerships to fund operations and development.
• Forbearance agreements are not uncommon when companies face short-term liquidity issues.
• The increase in payment percentage to 25% is a significant concession, indicating the company's weak negotiating position.
• Companies like Veru, which have divested assets, often seek to maximize returns from these transactions through such agreements.
• The reliance on an equity line of credit for immediate cash needs is a common but risky strategy for companies with limited cash reserves.

Stakeholder Impact

• Shareholders may be concerned about the company's financial stability and increased obligations.
• Creditors may be wary of the company's ability to meet its financial obligations.
• Employees may be concerned about the company's long-term viability.

Next Steps

• Onconetix needs to secure at least $97,000 from its equity line of credit to trigger the delayed payment to Veru.
• The company will need to manage its cash flow carefully to meet the increased payment obligations to Veru.
• Onconetix will need to continue to seek financing and strategic transactions to meet its obligations.

Key Dates

Keywords

Forbearance Agreement, Asset Purchase Agreement, Debt Financing, Equity Line of Credit, Payment Waiver, Onconetix, Veru, Financial Obligations